GHO Capital Partners LLP, a European investor in global healthcare, and the Vistria Group, a middle-market private investment firm, have acquired Alcami Corp., a pharmaceutical contract development and manufacturing organization (CDMO), from Madison Dearborn Partners and Ampersand Capital Partners.

Headquartered in North Carolina, Alcami offers drug product manufacturing services focusing on sterile fill-finish of biologics and small molecules, and also offers formulation development, lab services and current good manufacturing practice (cGMP) bio-storage of temperature-sensitive biologics, pharmaceuticals and materials. GHO Capital and the Vistria Group will have a 50/50 controlling interest in Alcami. Ampersand and Alcami management will reinvest significant equity as part of the acquisition.

 “This is an ideal partnership in furthering Alcami’s strategic transformation, unprecedented growth rate and comprehensive service offerings valued by over 1,000 clients around the globe,” comments Patrick Walsh, chairman and CEO of Alcami. “GHO and the Vistria Group have excellent reputations for partnering with high-growth companies that create value for all stakeholders.

Ropes & Gray LLP acted as legal advisor to GHO Capital and The Vistria Group, Jefferies Group LLC and OES acted as buy-side financial advisors, McKinsey as commercial diligence advisor, Deloitte as financial and tax due diligence advisor, EY as ESG advisor and Lockton as insurance advisor. Financing is provided by credit funds managed by Ares Management, as administrative agent and lead arranger. Morgan Stanley & Co. LLC is serving as financial advisor and Kirkland & Ellis LLP is serving as legal advisor to Alcami.